Objective: To evaluate the response and the side effects of Iressa on the first line treatment in senium advanced stage non-small cell lung cancer. Methods: Sixteen non-small cell lung cancer patients were observed fr...Objective: To evaluate the response and the side effects of Iressa on the first line treatment in senium advanced stage non-small cell lung cancer. Methods: Sixteen non-small cell lung cancer patients were observed from November 2005 to September 2007, the date of patients belong to the Second Affiliated Hospital of Dalian Medical University. I was prescribed on the first line at oral dose of 250 mg daily as a continuous dose. Then the response and side-effects of Iressa were evalu-ated. Results: Among 16 patients, CR, PR, SD, PD were 0% (0/16), 37.5% (6/16), 50% (8/16), 12.5% (2/16) respectively. CR + PR + SD was 87.5% (14/16). Adverse events: rash 37.5% (6/16), dry skin 18.75% (3/16), itching of skin 12.5% (2/16), diarrhea 31.25 (5/16), and hepatic dysfunction (GPT increase) 12.5% (2/16). Conclusion: Iressa is active on the first line treatment in old age advanced stage non-small cell lung cancer. It is well tolerated with adverse events. The quality of life may be improved significantly.展开更多
文摘Objective: To evaluate the response and the side effects of Iressa on the first line treatment in senium advanced stage non-small cell lung cancer. Methods: Sixteen non-small cell lung cancer patients were observed from November 2005 to September 2007, the date of patients belong to the Second Affiliated Hospital of Dalian Medical University. I was prescribed on the first line at oral dose of 250 mg daily as a continuous dose. Then the response and side-effects of Iressa were evalu-ated. Results: Among 16 patients, CR, PR, SD, PD were 0% (0/16), 37.5% (6/16), 50% (8/16), 12.5% (2/16) respectively. CR + PR + SD was 87.5% (14/16). Adverse events: rash 37.5% (6/16), dry skin 18.75% (3/16), itching of skin 12.5% (2/16), diarrhea 31.25 (5/16), and hepatic dysfunction (GPT increase) 12.5% (2/16). Conclusion: Iressa is active on the first line treatment in old age advanced stage non-small cell lung cancer. It is well tolerated with adverse events. The quality of life may be improved significantly.
